Journal Article

DKFZ-2024-01529

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png The Safety Profile of Vitamin D Supplements Using Real-World Data from 445,493 Participants of the UK Biobank: Slightly Higher Hypercalcemia Prevalence but Neither Increased Risks of Kidney Stones nor Atherosclerosis.

Sha, S. (First author)DKFZ* ; Degen, M.DKFZ* ; Vlaski, T.DKFZ* ; Fan, Z.DKFZ* ; Brenner, H. (Last author)DKFZ* ; Schöttker, B. (Last author)DKFZ*

2024
MDPI Basel

This record in other databases:  

Please use a persistent id in citations: doi:10.3390/nu16142251

Abstract: Background: Potential calcium-related adverse events of vitamin D supplement use have not been addressed in large-scale, real-world data so far. Methods: Leveraging data from the UK Biobank, encompassing 445,493 individuals aged 40-69, we examined associations of high 25-hydroxyvitamin (25(OH)D) levels ≥ 100 nmol/L and vitamin D supplementation with hypercalcemia (serum calcium > 2.6 mmol/L), kidney stones, and atherosclerosis assessments (pulse wave arterial stiffness index and carotid intima-medial thickness). Regression models were comprehensively adjusted for 49 covariates. Results: Approximately 1.5% of the participants had high 25(OH)D levels, 4.3% regularly used vitamin D supplements, and 20.4% reported regular multivitamin use. At baseline, the hypercalcemia prevalence was 1.6%, and 1.1% was diagnosed with kidney stones during follow-up. High 25(OH)D levels were neither associated with calcium-related adverse events nor atherosclerosis assessments. Vitamin D and multivitamin supplementation were associated with an increased prevalence of hypercalcemia (odds ratios and 95% confidence intervals: 1.46 [1.32-1.62] and 1.11 [1.04-1.18], respectively) but were neither associated with atherosclerosis nor future kidney stones. Conclusions: High 25(OH)D levels observable in routine care were not associated with any adverse outcome. Vitamin D users have a slightly higher prevalence of hypercalcemia, possibly due to co-supplementation with calcium, but without a higher atherosclerosis prevalence or risk of kidney stones.

Keyword(s): Humans (MeSH) ; Hypercalcemia: epidemiology (MeSH) ; Hypercalcemia: chemically induced (MeSH) ; Vitamin D: analogs & derivatives (MeSH) ; Vitamin D: blood (MeSH) ; Vitamin D: administration & dosage (MeSH) ; Middle Aged (MeSH) ; Male (MeSH) ; Female (MeSH) ; Dietary Supplements: adverse effects (MeSH) ; United Kingdom: epidemiology (MeSH) ; Kidney Calculi: epidemiology (MeSH) ; Kidney Calculi: blood (MeSH) ; Aged (MeSH) ; Atherosclerosis: epidemiology (MeSH) ; Atherosclerosis: etiology (MeSH) ; Adult (MeSH) ; Prevalence (MeSH) ; Biological Specimen Banks (MeSH) ; Risk Factors (MeSH) ; Calcium: blood (MeSH) ; Calcium: administration & dosage (MeSH) ; UK Biobank (MeSH) ; adverse events ; atherosclerosis ; hypercalcemia ; kidney stone risk ; real-world evidence ; serum 25-hydroxyvitamin D levels ; vitamin D supplementation ; Vitamin D ; 25-hydroxyvitamin D ; Calcium

Note: #EA:C070#LA:C070#LA:C120#

---

Contributing Institute(s):

1. C070 Klinische Epidemiologie und Alternf. (C070)
2. Präventive Onkologie (C120)
3. DKTK HD zentral (HD01)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2024

---

Database coverage:
; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---